Enanta files lawsuit against Pfizer antiviral drug Paxlovid
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
- World first: An mRNA vaccine that can 100% protect against deadly bacterial infections is available
- The first successful use of CAR-T cells to treat severe muscle inflammation
Enanta files lawsuit against Pfizer antiviral drug Paxlovid
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Enanta files lawsuit against Pfizer antiviral drug Paxlovid.
A few days ago, Enanta Pharmaceuticals formally filed a patent infringement lawsuit against Pfizer, alleging Pfizer’s alleged use of Enanta’s proprietary antiviral ingredients in the production of the COVID-19 antiviral drug Paxlovid.
In a lawsuit filed in the U.S. District Court for the District of Massachusetts, Delaware-based Enanta said it would seek a court acknowledgment of Pfizer’s infringement and ask Pfizer to pay damages, legal fees and other financial compensation measures.
Enanta pointed out that Pfizer’s antiviral 3CL protease inhibitor drug candidate used in the manufacturing design of Paxlovid is suspected of knowingly infringing Enanta’s patents, especially EDP-235, which Entanta has identified as a COVID-19 virus as early as early 2021. 19 lead compounds for R&D projects.
The main component of Pfizer’s COVID-19 antiviral drug Paxlovid, nirmatrelvir, is a SARS-CoV-23CL protease inhibitor.
Enanta began dosing its first human subject in a Phase I trial as early as February and was granted Fast Track designation by the U.S. Food and Drug Administration in March. Enanta filed a U.S. provisional patent application (‘048) back in July 2020, and the company then formally filed a utility patent application in July 2021, claiming priority.
In November 2021, the company refiled U.S. Patent Application No. 17/522,176 (‘176) to further support the priority claim filed in the earlier application.
After the U.S. Patent Office recognized Enanta’s patented innovation in June of that year, the company was officially granted the ‘953 patent, which Enanta has claimed in its latest court action is that Pfizer violated the patent.
“Pfizer allegedly used unlawful means to import Paxlovid products into the United States by actively inducing manufacture, use, sale, or offer for sale within the Commit and continue to engage in these infringing practices without permission or authorization.”
Enanta also specifically stated that it does not intend to ask Pfizer to immediately stop the distribution of Paxlovid or file a lawsuit in related matters, because the company recognizes the importance of Paxlovid to control the current epidemic.
However, Enanta stressed that Pfizer’s infringement has and will continue to damage Enanta’s legal rights, so Enanta is fully entitled to the corresponding damages.
Enanta is also currently seeking triple damages for Pfizer’s willful tort and other financial damages related to the issue.
So far, Pfizer has not responded to the matter.
Reference source:
Enanta Sues Pfizer For Patent Infringement in COVID-19 Antiviral Paxlovid
Enanta files lawsuit against Pfizer antiviral drug Paxlovid
(source:internet, reference only)
Disclaimer of medicaltrend.org
